Selected research
Industry Research
Recombinant Antibody Expression Service Industry Research Report 2026
Market perspective
The global Recombinant Antibody Expression Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Recombinant Antibody Expression Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Recombinant Antibody Expression Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Recombinant Antibody Expression Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Recombinant Antibody Expression Service include GenScript Biotech, Creative Biolabs, Thermo Fisher Scientific, Bio-Rad Laboratories, Sino Biological, ProMab Biotechnologies, LakePharma(Curia), Profacgen and Atlas Antibodies, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Recombinant Antibody Expression Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Recombinant Antibody Expression Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Recombinant Antibody Expression Service Market by Company
GenScript Biotech
Creative Biolabs
Thermo Fisher Scientific
Bio-Rad Laboratories
Sino Biological
ProMab Biotechnologies
LakePharma(Curia)
Profacgen
Atlas Antibodies
Absolute Antibody
ProteoGenix
Rockland Immunochemicals
Proteintech
RayBiotech
BioLegend
Agilent Technologies
Novus Biologicals
OriGene Technologies
ACROBiosystems
Fitzgerald Industries(Biosynth)
Azenta Life Sciences
R&D Systems
Abnova
WuXi Biologics
Biointron Biological
Detai Bio-Tech
cusabio
FITGENE
GentleGen
TekBiotech
Recombinant Antibody Expression Service Segment by Type
Recombinant Protein Mammalian Expression Service
Chimeric Antibody Expression Service
Recombinant Fragment Antibody Expression Service
VHH Nanobody Expression Service
Recombinant Antibody Expression Service Segment by Application
Scientific Research
Immunodiagnostics
Antibody Drug Development
Others
Recombinant Antibody Expression Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Antibody Expression Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Antibody Expression Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Antibody Expression Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Recombinant Antibody Expression Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Protein Mammalian Expression Service
- Chimeric Antibody Expression Service
- Recombinant Fragment Antibody Expression Service
- VHH Nanobody Expression Service
Applications
- Scientific Research
- Immunodiagnostics
- Antibody Drug Development
- Others
Companies covered
- GenScript Biotech
- Creative Biolabs
- Thermo Fisher Scientific
- Bio-Rad Laboratories
- Sino Biological
- ProMab Biotechnologies
- LakePharma(Curia)
- Profacgen
- Atlas Antibodies
- Absolute Antibody
- ProteoGenix
- Rockland Immunochemicals
- Proteintech
- RayBiotech
- BioLegend
- Agilent Technologies
- Novus Biologicals
- OriGene Technologies
- ACROBiosystems
- Fitzgerald Industries(Biosynth)
- Azenta Life Sciences
- R&D Systems
- Abnova
- WuXi Biologics
- Biointron Biological
- Detai Bio-Tech
- cusabio
- FITGENE
- GentleGen
- TekBiotech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Recombinant Antibody Expression Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Recombinant Protein Mammalian Expression Service
- 2.2.3 Chimeric Antibody Expression Service
- 2.2.4 Recombinant Fragment Antibody Expression Service
- 2.2.5 VHH Nanobody Expression Service
- 2.3 Recombinant Antibody Expression Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Scientific Research
- 2.3.3 Immunodiagnostics
- 2.3.4 Antibody Drug Development
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Recombinant Antibody Expression Service Breakdown Data by Type
- 3.1 Global Recombinant Antibody Expression Service Historic Market Size by Type (2021-2026)
- 3.2 Global Recombinant Antibody Expression Service Forecasted Market Size by Type (2027-2032)
4 Recombinant Antibody Expression Service Breakdown Data by Application
- 4.1 Global Recombinant Antibody Expression Service Historic Market Size by Application (2021-2026)
- 4.2 Global Recombinant Antibody Expression Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Recombinant Antibody Expression Service Market Perspective (2021-2032)
- 5.2 Global Recombinant Antibody Expression Service Growth Trends by Region
- 5.2.1 Global Recombinant Antibody Expression Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Recombinant Antibody Expression Service Historic Market Size by Region (2021-2026)
- 5.2.3 Recombinant Antibody Expression Service Forecasted Market Size by Region (2027-2032)
- 5.3 Recombinant Antibody Expression Service Market Dynamics
- 5.3.1 Recombinant Antibody Expression Service Industry Trends
- 5.3.2 Recombinant Antibody Expression Service Market Drivers
- 5.3.3 Recombinant Antibody Expression Service Market Challenges
- 5.3.4 Recombinant Antibody Expression Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Recombinant Antibody Expression Service Players by Revenue
- 6.1.1 Global Top Recombinant Antibody Expression Service Players by Revenue (2021-2026)
- 6.1.2 Global Recombinant Antibody Expression Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Recombinant Antibody Expression Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Recombinant Antibody Expression Service Head Office and Area Served
- 6.4 Global Recombinant Antibody Expression Service Players, Product Type & Application
- 6.5 Global Recombinant Antibody Expression Service Manufacturers Established Date
- 6.6 Global Recombinant Antibody Expression Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Recombinant Antibody Expression Service Market Size (2021-2032)
- 7.2 North America Recombinant Antibody Expression Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Recombinant Antibody Expression Service Market Size by Country (2021-2026)
- 7.4 North America Recombinant Antibody Expression Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Recombinant Antibody Expression Service Market Size (2021-2032)
- 8.2 Europe Recombinant Antibody Expression Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Recombinant Antibody Expression Service Market Size by Country (2021-2026)
- 8.4 Europe Recombinant Antibody Expression Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Recombinant Antibody Expression Service Market Size (2021-2032)
- 9.2 Asia-Pacific Recombinant Antibody Expression Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Recombinant Antibody Expression Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Recombinant Antibody Expression Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Recombinant Antibody Expression Service Market Size (2021-2032)
- 10.2 South America Recombinant Antibody Expression Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Recombinant Antibody Expression Service Market Size by Country (2021-2026)
- 10.4 South America Recombinant Antibody Expression Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Recombinant Antibody Expression Service Market Size (2021-2032)
- 11.2 Middle East & Africa Recombinant Antibody Expression Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Recombinant Antibody Expression Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Recombinant Antibody Expression Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 GenScript Biotech
- 12.1.1 GenScript Biotech Company Information
- 12.1.2 GenScript Biotech Business Overview
- 12.1.3 GenScript Biotech Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.1.4 GenScript Biotech Recombinant Antibody Expression Service Product Portfolio
- 12.1.5 GenScript Biotech Recent Developments
- 12.2 Creative Biolabs
- 12.2.1 Creative Biolabs Company Information
- 12.2.2 Creative Biolabs Business Overview
- 12.2.3 Creative Biolabs Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.2.4 Creative Biolabs Recombinant Antibody Expression Service Product Portfolio
- 12.2.5 Creative Biolabs Recent Developments
- 12.3 Thermo Fisher Scientific
- 12.3.1 Thermo Fisher Scientific Company Information
- 12.3.2 Thermo Fisher Scientific Business Overview
- 12.3.3 Thermo Fisher Scientific Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.3.4 Thermo Fisher Scientific Recombinant Antibody Expression Service Product Portfolio
- 12.3.5 Thermo Fisher Scientific Recent Developments
- 12.4 Bio-Rad Laboratories
- 12.4.1 Bio-Rad Laboratories Company Information
- 12.4.2 Bio-Rad Laboratories Business Overview
- 12.4.3 Bio-Rad Laboratories Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.4.4 Bio-Rad Laboratories Recombinant Antibody Expression Service Product Portfolio
- 12.4.5 Bio-Rad Laboratories Recent Developments
- 12.5 Sino Biological
- 12.5.1 Sino Biological Company Information
- 12.5.2 Sino Biological Business Overview
- 12.5.3 Sino Biological Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.5.4 Sino Biological Recombinant Antibody Expression Service Product Portfolio
- 12.5.5 Sino Biological Recent Developments
- 12.6 ProMab Biotechnologies
- 12.6.1 ProMab Biotechnologies Company Information
- 12.6.2 ProMab Biotechnologies Business Overview
- 12.6.3 ProMab Biotechnologies Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.6.4 ProMab Biotechnologies Recombinant Antibody Expression Service Product Portfolio
- 12.6.5 ProMab Biotechnologies Recent Developments
- 12.7 LakePharma(Curia)
- 12.7.1 LakePharma(Curia) Company Information
- 12.7.2 LakePharma(Curia) Business Overview
- 12.7.3 LakePharma(Curia) Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.7.4 LakePharma(Curia) Recombinant Antibody Expression Service Product Portfolio
- 12.7.5 LakePharma(Curia) Recent Developments
- 12.8 Profacgen
- 12.8.1 Profacgen Company Information
- 12.8.2 Profacgen Business Overview
- 12.8.3 Profacgen Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.8.4 Profacgen Recombinant Antibody Expression Service Product Portfolio
- 12.8.5 Profacgen Recent Developments
- 12.9 Atlas Antibodies
- 12.9.1 Atlas Antibodies Company Information
- 12.9.2 Atlas Antibodies Business Overview
- 12.9.3 Atlas Antibodies Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.9.4 Atlas Antibodies Recombinant Antibody Expression Service Product Portfolio
- 12.9.5 Atlas Antibodies Recent Developments
- 12.10 Absolute Antibody
- 12.10.1 Absolute Antibody Company Information
- 12.10.2 Absolute Antibody Business Overview
- 12.10.3 Absolute Antibody Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.10.4 Absolute Antibody Recombinant Antibody Expression Service Product Portfolio
- 12.10.5 Absolute Antibody Recent Developments
- 12.11 ProteoGenix
- 12.11.1 ProteoGenix Company Information
- 12.11.2 ProteoGenix Business Overview
- 12.11.3 ProteoGenix Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.11.4 ProteoGenix Recombinant Antibody Expression Service Product Portfolio
- 12.11.5 ProteoGenix Recent Developments
- 12.12 Rockland Immunochemicals
- 12.12.1 Rockland Immunochemicals Company Information
- 12.12.2 Rockland Immunochemicals Business Overview
- 12.12.3 Rockland Immunochemicals Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.12.4 Rockland Immunochemicals Recombinant Antibody Expression Service Product Portfolio
- 12.12.5 Rockland Immunochemicals Recent Developments
- 12.13 Proteintech
- 12.13.1 Proteintech Company Information
- 12.13.2 Proteintech Business Overview
- 12.13.3 Proteintech Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.13.4 Proteintech Recombinant Antibody Expression Service Product Portfolio
- 12.13.5 Proteintech Recent Developments
- 12.14 RayBiotech
- 12.14.1 RayBiotech Company Information
- 12.14.2 RayBiotech Business Overview
- 12.14.3 RayBiotech Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.14.4 RayBiotech Recombinant Antibody Expression Service Product Portfolio
- 12.14.5 RayBiotech Recent Developments
- 12.15 BioLegend
- 12.15.1 BioLegend Company Information
- 12.15.2 BioLegend Business Overview
- 12.15.3 BioLegend Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.15.4 BioLegend Recombinant Antibody Expression Service Product Portfolio
- 12.15.5 BioLegend Recent Developments
- 12.16 Agilent Technologies
- 12.16.1 Agilent Technologies Company Information
- 12.16.2 Agilent Technologies Business Overview
- 12.16.3 Agilent Technologies Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.16.4 Agilent Technologies Recombinant Antibody Expression Service Product Portfolio
- 12.16.5 Agilent Technologies Recent Developments
- 12.17 Novus Biologicals
- 12.17.1 Novus Biologicals Company Information
- 12.17.2 Novus Biologicals Business Overview
- 12.17.3 Novus Biologicals Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.17.4 Novus Biologicals Recombinant Antibody Expression Service Product Portfolio
- 12.17.5 Novus Biologicals Recent Developments
- 12.18 OriGene Technologies
- 12.18.1 OriGene Technologies Company Information
- 12.18.2 OriGene Technologies Business Overview
- 12.18.3 OriGene Technologies Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.18.4 OriGene Technologies Recombinant Antibody Expression Service Product Portfolio
- 12.18.5 OriGene Technologies Recent Developments
- 12.19 ACROBiosystems
- 12.19.1 ACROBiosystems Company Information
- 12.19.2 ACROBiosystems Business Overview
- 12.19.3 ACROBiosystems Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.19.4 ACROBiosystems Recombinant Antibody Expression Service Product Portfolio
- 12.19.5 ACROBiosystems Recent Developments
- 12.20 Fitzgerald Industries(Biosynth)
- 12.20.1 Fitzgerald Industries(Biosynth) Company Information
- 12.20.2 Fitzgerald Industries(Biosynth) Business Overview
- 12.20.3 Fitzgerald Industries(Biosynth) Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.20.4 Fitzgerald Industries(Biosynth) Recombinant Antibody Expression Service Product Portfolio
- 12.20.5 Fitzgerald Industries(Biosynth) Recent Developments
- 12.21 Azenta Life Sciences
- 12.21.1 Azenta Life Sciences Company Information
- 12.21.2 Azenta Life Sciences Business Overview
- 12.21.3 Azenta Life Sciences Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.21.4 Azenta Life Sciences Recombinant Antibody Expression Service Product Portfolio
- 12.21.5 Azenta Life Sciences Recent Developments
- 12.22 R&D Systems
- 12.22.1 R&D Systems Company Information
- 12.22.2 R&D Systems Business Overview
- 12.22.3 R&D Systems Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.22.4 R&D Systems Recombinant Antibody Expression Service Product Portfolio
- 12.22.5 R&D Systems Recent Developments
- 12.23 Abnova
- 12.23.1 Abnova Company Information
- 12.23.2 Abnova Business Overview
- 12.23.3 Abnova Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.23.4 Abnova Recombinant Antibody Expression Service Product Portfolio
- 12.23.5 Abnova Recent Developments
- 12.24 WuXi Biologics
- 12.24.1 WuXi Biologics Company Information
- 12.24.2 WuXi Biologics Business Overview
- 12.24.3 WuXi Biologics Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.24.4 WuXi Biologics Recombinant Antibody Expression Service Product Portfolio
- 12.24.5 WuXi Biologics Recent Developments
- 12.25 Biointron Biological
- 12.25.1 Biointron Biological Company Information
- 12.25.2 Biointron Biological Business Overview
- 12.25.3 Biointron Biological Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.25.4 Biointron Biological Recombinant Antibody Expression Service Product Portfolio
- 12.25.5 Biointron Biological Recent Developments
- 12.26 Detai Bio-Tech
- 12.26.1 Detai Bio-Tech Company Information
- 12.26.2 Detai Bio-Tech Business Overview
- 12.26.3 Detai Bio-Tech Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.26.4 Detai Bio-Tech Recombinant Antibody Expression Service Product Portfolio
- 12.26.5 Detai Bio-Tech Recent Developments
- 12.27 cusabio
- 12.27.1 cusabio Company Information
- 12.27.2 cusabio Business Overview
- 12.27.3 cusabio Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.27.4 cusabio Recombinant Antibody Expression Service Product Portfolio
- 12.27.5 cusabio Recent Developments
- 12.28 FITGENE
- 12.28.1 FITGENE Company Information
- 12.28.2 FITGENE Business Overview
- 12.28.3 FITGENE Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.28.4 FITGENE Recombinant Antibody Expression Service Product Portfolio
- 12.28.5 FITGENE Recent Developments
- 12.29 GentleGen
- 12.29.1 GentleGen Company Information
- 12.29.2 GentleGen Business Overview
- 12.29.3 GentleGen Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.29.4 GentleGen Recombinant Antibody Expression Service Product Portfolio
- 12.29.5 GentleGen Recent Developments
- 12.30 TekBiotech
- 12.30.1 TekBiotech Company Information
- 12.30.2 TekBiotech Business Overview
- 12.30.3 TekBiotech Revenue in Recombinant Antibody Expression Service Business (2021-2026)
- 12.30.4 TekBiotech Recombinant Antibody Expression Service Product Portfolio
- 12.30.5 TekBiotech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst